Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析

【英語タイトル】Vertex Pharmaceuticals Inc (VRTX) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C15901)・商品コード:DATA904C15901
・発行会社(調査会社):GlobalData
・発行日:2019年4月
・ページ数:56
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Vertex Pharmaceuticals Inc (VRTX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF). Through its research and development (R&D) efforts, the company focuses on influenza, cancer, neurological diseases and disorders including pain and cystic fibrosis. Vertex has R&D centers and commercial offices in North America, South America, Europe and Australia. The company offers its products in the US, Europe, Australia and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

Vertex Pharmaceuticals Inc Key Recent Developments

Apr 02,2019 Vertex Pharmaceuticals names Charles Wagner as Chief Financial Officer
Feb 21,2019 Vertex appoints Lloyd Carney to its board of directors
Feb 05,2019 Vertex reports full-year and fourth-quarter 2018 financial results
Jan 23,2019 Vertex announces departure of Ian Smith, names interim CFO

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Vertex Pharmaceuticals Inc – Key Facts
Vertex Pharmaceuticals Inc – Key Employees
Vertex Pharmaceuticals Inc – Key Employee Biographies
Vertex Pharmaceuticals Inc – Major Products and Services
Vertex Pharmaceuticals Inc – History
Vertex Pharmaceuticals Inc – Company Statement
Vertex Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Vertex Pharmaceuticals Inc – Business Description
Business Segment: Pharmaceuticals
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Others
Performance
Geographical Segment: United States
Performance
R&D Overview
Vertex Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Vertex Pharmaceuticals Inc – Strengths
Vertex Pharmaceuticals Inc – Weaknesses
Vertex Pharmaceuticals Inc – Opportunities
Vertex Pharmaceuticals Inc – Threats
Vertex Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Vertex Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 02, 2019: Vertex Pharmaceuticals names Charles Wagner as Chief Financial Officer
Feb 21, 2019: Vertex appoints Lloyd Carney to its board of directors
Feb 05, 2019: Vertex reports full-year and fourth-quarter 2018 financial results
Jan 23, 2019: Vertex announces departure of Ian Smith, names interim CFO
Oct 24, 2018: Vertex reports third-quarter 2018 financial results
Oct 16, 2018: Vertex Pharmaceuticals selects Kinaxis to manage supply chain
Oct 10, 2018: CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
Oct 04, 2018: Vertex’s cystic fibrosis drugs become publicly available in Denmark
Sep 10, 2018: Vertex Pharmaceuticals names Katharine Jensen as head of corporate social responsibility
Sep 06, 2018: Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis[Newswire : Healthcare-BW] Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Vertex Pharmaceuticals Inc, Key Facts
Vertex Pharmaceuticals Inc, Key Employees
Vertex Pharmaceuticals Inc, Key Employee Biographies
Vertex Pharmaceuticals Inc, Major Products and Services
Vertex Pharmaceuticals Inc, History
Vertex Pharmaceuticals Inc, Subsidiaries
Vertex Pharmaceuticals Inc, Key Competitors
Vertex Pharmaceuticals Inc, Ratios based on current share price
Vertex Pharmaceuticals Inc, Annual Ratios
Vertex Pharmaceuticals Inc, Annual Ratios (Cont...1)
Vertex Pharmaceuticals Inc, Annual Ratios (Cont...2)
Vertex Pharmaceuticals Inc, Interim Ratios
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Vertex Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Vertex Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Vertex Pharmaceuticals Inc, Ratio Charts
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★調査レポート[Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析] (コード:DATA904C15901)販売に関する免責事項を必ずご確認ください。
★調査レポート[Vertex Pharmaceuticals Inc (VRTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆